Skip to product information
NaN of -Infinity

  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Gaviscon Advance Mint Chewable- 24 Tablets

Gaviscon Advance Mint Chewable- 24 Tablets

  • Ozempic®️-equivalent therapy now available for weight management
  • Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • May help reduce osteoarthritis-related pain
  • Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • Supports cardiovascular risk reduction
  • Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £7.99
Sale price £7.99
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

What is Gaviscon Advance Mint Chewable - 24 Tablets?

  • Gaviscon Advance Mint Chewable is a medication available in the form of chewable tablets.
  • It is designed to provide relief from symptoms of heartburn and acid reflux.
  • Each pack contains 24 tablets.

Directions for Use:

  • Chew the tablets thoroughly before swallowing.
  • For adults and children over 12 years old, take 1 to 2 tablets after meals and before bedtime.
  • Do not exceed the recommended dose.

Warnings:

  • Avoid taking Gaviscon Advance Mint Chewable if you are allergic to any of the ingredients.
  • Consult a doctor before use if you are pregnant, breastfeeding, or have kidney problems.
  • If symptoms persist after the recommended dose, seek medical advice.

Side Effects:

  • Some possible side effects may include constipation or diarrhea.
  • If you experience any unusual or severe side effects, discontinue use and consult a healthcare professional.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2088658
Muzammil Peerally

Authored by:

Muzammil Peerally

Superintendent Pharmacist

GPhC Number: 2232689
Tarun Kumar

Reviewed by:

Tarun Kumar

Clinical Leads

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities